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Abstract
From the 13th to 16th February 2017, researchers from around the world convened for the 24th annual Conference on
Retroviruses and Opportunistic Infections (CROI) at the Washington State Convention Center in Seattle, Washington.
The conference was organised by the International Antiviral Society-USA (IAS-USA) in partnership with the CROI Foundation.
The conference included over 1000 oral and poster presentations of peer-reviewed original research as well as lectures
and symposia featuring insights from leading basic, translational and clinical researchers. Highlighted here are key data
presented at the conference.
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Introduction
The Conference on Retroviruses and Opportunistic Infections (CROI)
was established in 1993 and has grown to become the pre-eminent
HIV research meeting, providing a forum for researchers from all
disciplines and from around the world to share and discuss cutting-
edge HIV research. This year, the conference featured 905 poster
presentations and 96 oral presentations of peer-reviewed, original
research. International experts presented lectures and participated
in symposia addressing many aspects of HIV pathophysiology,
prevention, management and eradication. This report summarises
some of the major findings presented at the conference.
HIV prevention
Pre-exposure prophylaxis (PrEP) with tenofovir/emtricitabine
continues to expand rapidly as an HIV prevention method for men
who have sex with men (MSM) and other high-risk populations.
This year‘s conference included the first report of transmission
of wild-type HIV in a man with good PrEP adherence [1]. The
research team from Amsterdam reported that the man had been
taking PrEP with good adherence for 8 months when he
experienced seroconversion with both an indeterminate HIV
antibody test and Western blot, and negative HIV RNA. PrEP was
stopped over concerns about inducing potential resistance, and
within 3 weeks HIV RNA became positive with wild-type virus,
demonstrating no genotypic evidence of drug resistance to
tenofovir/emtricitabine or other antiretroviral therapy (ART).
Tenofovir levels on dried blood spot were consistent with daily
dosing. During the 8 months he was on PrEP, the man reported
condomless anal sex with a median of three to five sex partners
per day, and up to 75 different sex partners per month. He also
reported frequent drug use, including amphetamine, cocaine,
GHB/GBL, mephedrone and ketamine. The authors speculated that
HIV transmission might be attributable to an extremely high rate
of sexual exposure with potential mucosal damage. They also
hypothesised that lower levels of PrEP drugs in the rectal mucosa
than in the blood could have contributed to the transmission.
Retail pharmacies as service delivery points were evaluated in two
studies. In Seattle, a community pharmacy started by 245 individuals
(84% MSM) on PrEP and had 75% retention at 1 year [2]. The model
was cost-effective, recouping start-up costs within 9 months. In
Virginia, HIV testing was added to existing laboratory services as part
of a public/private partnership in a network of 32 retail pharmacies
[3]. In 2 years, 3221 HIV tests were performed, of which 25 (0.8%)
were positive. Many of those tested (46%) and most of those with
positive results (64%) were first-time testers with the majority of
testing (61%) being performed outside business hours.
Empirical evidence that combination HIV prevention can be
effective at reversing generalised epidemics came from the
well-studied Rakai region in Uganda, where, by 2016 scale-up of
medical circumcision, ART and viral suppression among those on
ART had all achieved levels of 60–75% [4]. From 2012 to 2016,
HIV incidence declined by 41%.
Antiretroviral therapy
A few years ago, there was a feeling that ART development was slowly
coming to an end. This was refuted once again at CROI with a rich
pipeline of medications in development, including nucleoside reverse
transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase
inhibitors (NNRTIs), protease inhibitors (PIs), integrase strand transfer
inhibitors (INSTIs), and capsid inhibitors, the latter of which represent
a new class of drugs. HIV-specific broadly neutralising monoclonal
antibodies were also highlighted this year for their potential roles in
both prevention and treatment of HIV.
Long-acting (LA) preparations are one of the most exciting recent
developments in ART and they were featured prominently at CROI.
They have the potential to simplify regimens and facilitate adherence
to therapy, thereby increasing virological suppression rates and
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potentially decreasing the development of drug resistance. Charles
Flexner from Johns Hopkins University provided an extensive review
of agents being developed for LA therapy, including novel agents
as well as reformulations of existing antiretroviral medications in
order to extend their half-life [5]. Agents discussed included, in
Phase I: EFda-MK8591; in Phase II: ibalizumab, PRO-140, albuvirtide
and broadly neutralising antibodies such as VRC01-LS, 3BNC117,
and 10-1074; and in Phase III: cabotegravir-LA and rilpivirine-LA.
Implants have been developed using tenofovir alafenamide (TAF),
which allow the drug to be released very slowly over a prolonged
period of several months.The implant with the new NRTI MK-8591
(EFdA) also produces prolonged drug levels. These implants can
be removed in case of toxicity.
Dr Flexner also described how nanoformulation can be used to
extend drug half-life, and this approach has been taken in the
development of LA versions of tenofovir (TDF), lopinavir (LPV),
ritonavir (r) and also in the case of dolutegravir (DTG) with a mixed
lineage kinase-3 inhibitor, URMC-099. Additionally, oral
nanoformulations of efavirenz (EFV) and LPV could potentially
reduce the dose of drugs and lead to lower costs [6]. Uptake of
drugs in lymph nodes is also enhanced by these nanoformulations.
At an early stage of development, researchers described a new class
of compounds with an untouched target: the HIV capsid, which plays
a role at several stages of the virus life cycle [7]. One compound,
GS-CA1, looks particularly promising due to some of its characteristics
such as high potency (EC50 of 140 picomolar), stability, low clearance
and good resistance profile and could be used as an extended-release
parenteral formulation for LA treatment. A new PI, GS-PI1, with the
potential for once-a-day administration with an absence of boosting,
was described at an early stage of development [8]. This novel
compound displayed potent inhibition of HIV replication in vitro with
less than two-fold reduction in potency in the presence of major
protease inhibitor resistance-associated mutations.
GS-9131, a monamidate prodrug of the nucleotide analogue GS 9148
has activity against NRTI-resistant strains, in subtypes A, B, C, D, E,
F, group O and N and also against HIV-2 and is not affected by reverse
transcriptase mutations such as K65R, L74V, M184V or their
combination, and has a potential for once-daily dosing [9]. Bictegravir
(BIC) is a new potent and unboosted INSTI with in vitro activity against
wild-type and most INSTI-resistant variants. It has shown more than
a 2-log decrease in a 10-day study [10]. When comparing BIC to
dolutegravir (DTG) with FTC/TAF for initial therapy in ART-naive
individuals (almost all male, median CD4 cell count around 450
cells/mm3), in a Phase IIb double-blind, randomised trial, this new
integrase inhibitor has shown a high rate of viral suppression (<50
copies/mL=primary end-point) at 48 weeks, e.g. 97% vs 91% for
BIC and DTG, respectively, with no emergence of resistance through
week 48, and good safety and tolerability for both compounds. There
are four Phase III, fully enrolled, ongoing clinical trials assessing safety,
efficacy and tolerability of the compound.
Among the agents in a more advanced stage of development is
doravirine (DOR), which is a next-generation NNRTI with in vitro
activity against wild-type virus as well as virus with many common
NNRTI-resistancemutations (K103N,Y181C, G190A, K103N/Y181C
and E138K). It also demonstrated a superior neuropsychiatric profile
when compared to efavirenz in a Phase IIb trial. Presented at CROI
were the results of a Phase III treatment-naive trial (DRIVE-
FORWARD) with TDF-3TC/ABC-3TC background plus DOR or
darunavir/ritonavir (DRV/r) [11].This study showed non-inferiority
of DOR at 100mg as a once-daily regimen on the primary end-point
(VL<50 copies/mL, 84% vs 80% for DOR and DRV/r, respectively).
Side effects were similar between arms. Discontinuation rates were
quite high (DOR of 15% and DVR/R of 19%), which authors
speculated could have been caused by the high-pill burden of these
regimens. Doravirine showed a superior lipid profile as compared
to DRV/r (fasting LDL-C and non-HDL-C) and a low rate of
development of drug resistance.
Two Phase III, randomised, multicentre, open-label, parallel group
and non-inferiority studies (SWORD 1 and 2) have demonstrated
that the switch to a two-drug regimen, DTG and rilpivirine (RPV)
in virologically controlled individuals on INSTI, NNRTI or PI + two
NRTIs maintained virological suppression (<50 copies/mL) through
48 weeks with a neutral effect on lipids and was as effective as
a 3–4 drug combination [12].
In the case of multi-resistance and limited treatment options, there
was a very interesting presentation on ibalizumab, a humanised
monoclonal antibody that blocks HIV entry into CD4T lymphocytes
[13]. It is a long-acting compound in Phase III development for the
treatment of multi-drug resistant HIV infection by IV administration.
The 24-week data fromTMB-301, an open label study that recruited
40 individuals with very resistant virus and administered a loading
dose of ibalizumab 2 g and then 800 mg every 2 weeks with an
optimised background for 24 weeks, showed mean viral load change
from baseline of −1.6 log10 copies/mL and virological suppression to
below 50 copies/mL was achieved in 43% of individuals. More than
a 1-log decrease in viral load was observed in the first 2 weeks while
on monotherapy only. Interestingly, the pharmacokinetic profile of
bi-weekly ibalizumab 800 mg administered IM was comparable to the
profile of IV administration [14].
Recognising the anticipated expansion of INSTI use in sub-Saharan
Africa, data from two observational cohort studies were presented
that suggested an association between INSTI use and an increased
risk of immune reconstitution inflammatory syndrome (IRIS). In
the 144-week SINGLE trial, first-line DTG-based ART showed
improved tolerability compared to efavirenz, but no benefit in terms
of preventing virological failure [15]. Thousands of individuals in
Botswana have already started DTG as part of their initial regimens
for HIV infection. IRIS occurs most often during first-line ART
initiation and, since INSTIs suppress HIV RNA levels more quickly
than other antiretroviral drug classes, the resulting rapid recovery
of immune function could cause immune reactions to existing
infections, often with severe effects. In a Dutch cohort study, IRIS
was either diagnosed by a clinician or classified by the French 2004
definition based on the observation of atypical tumour or
opportunistic infection accompanied by viral load decline or CD4
increase [16]. Utilising these definitions, researchers found that
38% of those who started ART with an INSTI and 16% of those
starting any other treatment regimen, developed IRIS. After
adjusting for other factors, participants prescribed INSTIs were
more likely to develop IRIS as compared to participants prescribed
other ART (odds ratio 3.25, 95% confidence interval [CI] 1.83–
5.80). In a French cohort study, severe IRIS leading to
hospitalisation developed in 3% of individuals in the INSTI group
versus 1.5% in the non-INSTI group, yielding a relative risk for
IRIS of 1.99 (95% CI 1.09–3.47) with INSTI-based ART [17]. IRIS
was most frequently related to tuberculosis, Mycobacterium avium
complex, and progressive multifocal leukoencephalopathy.
HIV eradication
The most discussed mechanism of HIV-1 reservoir persistence in
individuals on ART was the clonal proliferation of cells harbouring
the replication-competent proviral HIV-1, addressed in the themed
discussion ‘HIV persistence: clones, clones, and more clones’.
Guinevere Lee showed that only 7% of the HIV-1 DNA sequences
were genome-intact, where the defective genomes had large
deletions and APOBEC3G/3F-associated hypermutations [18].
Th1-polarised cells were found to harbour the highest proportion
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of genome-intact HIV-1 sequences with indication of clonal
expansion. Furthermore, Bonnie Hiener demonstrated clonal
expansions of cells with intact proviruses and identified effector
memory T cells (TEM) as the reservoir containing the highest
proportion of intact proviruses, demonstrating the importance of
targeting these cells in future eradication strategies [19]. In
addition, Zheng Wang proposed T cell activation and homeostatic
cytokines as potential mechanisms that induce the proliferation
of CD4 T cells carrying replication-competent HIV-1 [20].
Different research on HIV proteins and cellular RNAs was presented
within the selected themed discussion ‘Virus and cell RNA in HIV
replication’ and the symposium ‘Creating and destroying HIV capsids’.
First, Edmund Osei-Kuffour introduced a new host protein (USP18)
to abrogate SAMHD1 functioning inTamm-Horsfall Protein 1 (THP-1)
macrophage-like cells and upon overexpression resulting in increased
HIV infection [21]. Secondly, Wim Trypsteen highlighted the
importance of long non-coding RNAs in HIV infection in
transcriptome-wide screening during the different stages of the HIV
replication cycle, advocating further study of these molecules [22].
Also, several structural imaging studies (Cryo-EM) were presented
focusing on the mature and immature HIV capsid (CA) to understand
the process of maturation. In this context, the completed structure
of SP1-CA was elucidated by Hans-Georg Kräusslich and it was
repeated that mature CA performs all of its functions after cell entry
and acts as a transport module and reaction container for HIV genome
replication [23]. Other work by Barbie Ganser-Pornillos visualised the
mode-of-action of TRIM5α in CA degradation. Upon viral entry,
TRIM5α forms a 2-D hexagonal net over the CA and signals it for
ubiquitin-dependent downstream processes that lead to viral inhibition
and interferon signalling [24].
The use of gene therapy was discussed by Carl June in the plenary
‘Advances in cellular therapy in cancer and HIV’ [25]. Chimeric
antigen receptor (CAR) technology has diversified in the last
decade from engineered T cells with CAR of CD4 linked to the
CD3ζ signalling chain to the use of broadly neutralising antibodies
(bNAb) CAR, stem cells and HIV-resistant cells through CCR5 gene
editing. These showed promises in cell line or murine models and
the field awaits human data.
In the oral abstract session ‘HIV persistence and reactivation’,
Jeffrey Murry demonstrated the potency of TLR7 agonist GS-9620
to increase the immune-mediated clearance of HIV-infected cells
isolated from ART-suppressed individuals in vitro. GS-9620
stimulated both HIV production by infected CD4 T cells and their
elimination by cytolytic CD8 T cell activation or improved killing
by an effector antibody, indicating its potential within the
therapeutic vaccines or bNAbs [26].
Clinical studies of HIV cure
The topic of HIV cure featured prominently at CROI 2017. Jintanat
Ananworanich, in her plenary session outlined the major strategies
that may potentially contribute to viral control and the reduction of
the latent HIV reservoir, including the early initiation of ART, the use
of latency-reversing agents (LRA), and immune and gene therapies
[27]. She also presented data on the impact of early ART initiation
in participants who initiated treatment during Fiebig I in Bangkok,
Thailand [28]. In this study, eight participants (sevenmale, one female)
who had been virologically suppressed for a median of 2.8 years
underwent intensively monitored ART pause (IMAP). Despite
undetectable total HIV DNA and inducible HIV RNA in all participants
prior to IMAP, all experienced viral rebound with a median time to
rebound of 26 days. A pre-IMAP CD4/CD8 ratio ≤1 predicted time
to viral rebound (P=0.004). IMAP was safe, with no participants
developing symptoms consistent with an acute retroviral syndrome,
new resistance mutations or treatment failures after ART resumption.
Importantly, Beatriz Mothe shared results of a trial of therapeutic
vaccination and administration of a latency-reversing agent in a
rollover from the BCN01 study. Investigators showed amanipulation
of the CTL immunodominance pattern and viral control in some
of the participants in this study, in which 13 early-treated individuals
stopped ART after immunisation with MVA.HIVconsv vaccine,
followed by three, weekly doses of romidepsin and by a second
MVA.HIVconsv vaccination. To date, five participants remain off
ART after 7, 12, 14, 22 and 28 weeks, respectively [29]. In addition,
the data presented by Julie Mitchell suggested that plasmacytoid
dendritic cells (pDC) and non-classical monocytes were sensing
viral replication after stoppingART and might represent biomarkers
prior to viral rebound [30]. They observed increased levels of pDC,
non-classical monocytes and surface expression of PD-L1 and CD69
on pDCs prior to viral rebound.
The use of bNAbs in inducing HIV remission was discussed by Michel
Nussensweig [31]. Passive infusion of bNAb is associated with HIV
viral load reduction [32,33] and delayed time to viral rebound [34,35],
but also loss of efficacy due to the development of escape mutants.
In data presented at CROI by Sharon Riddler, 40 participants with
chronic HIV infection on ART with viral suppression were randomised
to either two or four infusions of VRCO1 at 40 mg/kg [36]. Although
these were safe and well-tolerated, no significant impact was made
on the HIV reservoir as measured by plasma single-copy HIV-RNA,
cell-associated HIV RNA/DNA, or stimulated virus production from
CD4T cells. Postulated mechanisms for the lack of response included
viral resistance to VRC01, poor penetration of VRC01 to sites of virus
replication, or inherent inability of VRC01 to clear virus particles or
virus-expressing cells.
Despite the single described case of HIV cure having occurred in the
setting of bone marrow transplantation (BMT) over 10 years ago,
this outcome has yet to be replicated [37]. In the Boston individuals,
despite the disappearance of a measurable reservoir of latent HIV
infection after BMT, HIV rebound was observed after ART was stopped
[38]. At CROI, new studies were presented to improve our
understanding of transplantation and HIV. Kobus Bosman presented
findings from IciStem, the largest multinational collaborative study
investigating the potential for HIV cure in HIV-infected individuals
requiring allogeneic stem cell transplantation for haematological
disorders [39]. Despite undetectable HIV-1 DNA in peripheral blood
mononuclear cells (PBMCs) of 11 HIV-infected individuals who
underwent transplantation with stem cells carrying the CCR5 Δ32
mutation, HIV-1 DNA persisted in tissues such as the ileum, liver,
spleen, lung, bone marrow and lymph node.
It has been postulated that selecting donors who enable the
establishment of full donor chimerism, and have the right natural killer
(NK) cell genetics to kill donor haematopoietic cells infected with HIV,
would eradicate HIV reservoirs formed post-transplant [40]. At CROI,
Adam Capoferri described HIV persistence in a patient who achieved
full donor chimerism in peripheral blood after allogeneic BMT, with
HIV measurable in resting memory CD4T cells by droplet digital PCR
(ddPCR), quantitative PCR (qPCR) and viral outgrowth assay [41].
Similar findings were reported by Alyssa Martin, who described
inducible HIV-1 latent reservoirs after HIV donor-positive and
donor-negative solid organ transplantation [42]. Latent reservoirs were
measured using a novel quantitative viral induction assay (QVIA) pre-
and post-transplantation in 17 HIV-infected recipients who were
maintained on ART. Further research is needed to determine the
impact of immunosuppressive or conditioning regimens on HIV
reservoirs, whether HIV reservoirs post-transplantation are being
expanded via infection of donor cells and/or clonal expansion of
donor/recipient-infected cells, and also to determine the optimal
timing for ART cessation post-transplantation in order to potentially
demonstrate HIV remission.
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Hepatitis C virus
Whilst there are few new drugs coming through the pipeline for
treating hepatitis C virus (HCV), the challenge of implementing
HCV cure strategies is beginning to emerge with data from
real-world cohorts of patients treated with directly acting antivirals
(DAAs). Anne Boerkamps presented experience from the
Netherlands of treating HCV in HIV co-infected patients [43]. DAAs
with pegylated interferon (pegIFN) and ribavirin were made
available for HIV/HCV co-infected patients with F3/F4 fibrosis
in 2014. By 2016, there was a national decision to make DAA-
based therapy available for all HIV/HCV co-infected patients
regardless of fibrosis stage. The cohort studied included 98% of
HIV-infected patients in care nationally, including 1400 HIV/HCV
co-infected individuals, of whom 1100 had received HCV treatment
by January 2017. Of those who had received treatment, 829
(59.3%) had successfully cleared the virus, 94 (6.7%) were still
on treatment and 197 (14.1%) had failed therapy. Of the 300
individuals who had not received HCV treatment, most were either
current injection-drug users, had poorly controlled HIV infection,
or were refugee females poorly engaged in care.
Laurent Cotte presented similar data from the DatAIDS cohort,
representing 25% of HIV-infected patients in France [44]. In this
French cohort, treatment was reported for more than 65% of all
HIV/HCV co-infected patients in care by the end of 2015, with
successful viral clearance in more than 60%. For those not able
to access DAAs via national programmes, Andrew Hill reported
data on viral clearance for 1150 individuals accessing DAAs via
‘buyers clubs’ in Australia, China, Russia and southeast Asia [45].
Generic DAAs were sourced from manufacturers in Bangladesh,
India, Egypt and China. Sustained virological response rates 12
weeks after therapy were greater than 95% across all genotypes
and fibrosis stages. Further data from the German Hepatitis C and
Co-infection (GECCO) cohort showed an 11% HCV re-infection
rate in MSM successfully treated for HCV with DAAs [46].
An epidemiological study in the Netherlands provided evidence for
the concept that treatment as prevention (TasP) may be effective at
decreasing the incidence of HCV infection [47]. Within 2 years after
the introduction of DAAs in the country in 2014, 65% of Dutch
HIV-infected MSM had initiated treatment and the incidence of acute
HCV infection in the group had declined by 53%. Moreover, the
decline in HCV incidence continued throughout 2016, and was 42%
lower in the second half of the year compared to the first half. In
contrast, syphilis rates increased during this period, suggesting a
biological link between HCV treatment and reduction in new infections
rather than temporal changes in risk behaviours.
There were two further datasets that gave important clues to the
continued drivers of the HCV epidemic amongst HIV-infected MSM
populations in Europe despite increasing access to unrestricted
DAAs. Elske Hoornenborg presented data from Amsterdam showing
that 4.8% of HIV-negative MSM enrolled on to an HIV PrEP
programme were infected with HCV [48]. Phylogenetic analyses
of the HCV NS5b sequences showed clustering with viruses
obtained from HIV/HCV co-infected MSM in the Netherlands,
suggesting transmission between HIV-infected and HIV-uninfected
MSM groups. This suggests a reversal of the previously described
sero-sorting risk behaviours and perhaps risk-compensation with
increasing availability of HIV PrEP. Dominique Braun presented
data from the Swiss HIV Cohort that, in preparation for an HCV
TasP project amongst HIV-infected MSM, prospectively screened
3722 individuals for HCV with RNA testing between December
2015 and May 2016 [49]. Incident HCV infection was diagnosed
in 17% of this cohort; 21% of whom were anti-HCV negative at
the time of diagnosis, suggesting that transmissions could easily
occur before HCV is diagnosed in routine care.
In summary, whilst access to treatment for HIV/HCV co-infected
individuals is increasing across Europe, treatment coverage is far
from universal. TasP for HCV appears to have reduced the incidence
among the HIV-infected MSM population in the Netherlands, but
data suggest that eradication of HCV in this group of individuals
is going to require a concerted effort to capture undiagnosed HCV
among HIV-infected and-uninfected MSM, address cross-border
transmissions, and provide early treatment with DAAs for all newly
diagnosed individuals with HCV, while continuing to promote
risk-reduction strategies to prevent new infections.
Sexually transmitted infections
Challenges and opportunities in sexually transmitted infections (STI)
control were highlighted in an early symposium at CROI. Scott
McClelland discussed the vaginal microbiome and susceptibility to
HIV, building upon several prospective studies that have explored this
relationship [50]. Emphasis was placed on the vaginal microbiota and
its potential to impact HIV susceptibility through pathways including
inflammation, immune mediators, HIV-inducing factors and disruption
of structural barriers. New interest in biomedical interventions for STIs
was discussed in the setting of increasing prevalence and incidence
of STIs in PrEP users [51]. Periodic presumptive treatment in female
sex workers with azithromycin has shown reduction in gonorrhoea
and chlamydia but not syphilis or HIV and studies using doxycycline
prophylaxis for MSM are ongoing. Matthew Golden showed that rates
of syphilis in high-income nations have been rising since 2000 [52].
This poses a challenge for clinicians but also presents an opportunity
for capitalising on the diagnosis to promote frequent HIV testing, PrEP
and condom use. Finally, Rebecca Guy described technological
advances in clinician point-of-care tests and self-testing at home that
could facilitate STI diagnosis for both routine clinical care and research
purposes [53].
Data from an STI post-exposure prophylaxis (PEP) sub-study of
the IPERGAY trial of PrEP were presented by Jean-Michel Molina
[54]. This study showed that a single oral dose of doxycycline
200 mg taken within 72 hours of condomless sex resulted in a
47% decline in STI incidence, including a 70% decline in Chlamydia
trachomatis infections and a 73% decrease in syphilis cases. There
was no significant effect on new Neisseria gonorrhoeae infections.
Opportunistic infections
A symposium emphasising TB and other opportunistic infections
discussed a broad array of recent developments. Results from a
multicentre diagnostic accuracy study of the Xpert Ultra illustrated
higher sensitivity than the Xpert in smear-negative and HIV-
infected individuals and improved accuracy for the detection of
rifampin (RIF) resistance [55]. However, a limitation included
detection of TB-DNA in some individuals with prior TB disease,
leading to reduced specificity of the assay overall. Results from
a previously published study assessing benefits of early ART and
6-month isoniazid prophylaxis (IPT) among HIV-infected adults
in Côte d’Ivoire were expanded to include results on the efficacy
of IPT in reducing long-term mortality [56]. These results showed
that, in adults with high CD4 cell counts, 6-month IPT led to a
39% decrease in mortality, independent of ART initiation and
baseline CD4 cell count. Finally, results of a randomised controlled
trial of prednisone for prevention of paradoxical TB-IRIS showed
that, in individuals at high risk of IRIS, prednisone during the first
4 weeks of ART reduced the risk of TB-IRIS by 30% and also
reduced the need for corticosteroids to treat TB-IRIS by 53% [57].
New data on HIV-related cryptococcal meningitis were also
presented at the Conference. The prevalence of advanced HIV
disease and cryptococcal infection (CI) in Botswana was
highlighted, emphasising that almost one in five inpatients with
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a CD4 cell count <100 cells/μL had CI [58]. A Phase II,
randomised, non-inferiority trial examining early fungicidal activity
(EFA) of three short-course high-dose liposomal amphotericin B
(L-AmB) schedules showed that single doses of 10 mg/kg L-AmB
were well tolerated and lead to non-inferior EFA as compared to
14-day courses of 3 mg/kg L-AmB in HIV-associated CM [59].
Results are being taken forward to a Phase III clinical endpoint
trial.
Ageing and inflammation
Judith S Currier from Los Angeles highlighted new insights into
long-term complications of HIV infection during the preconference
session for new investigators and trainees, including cardiovascular
disease (CVD), non-AIDS cancers, osteoporosis, diabetes mellitus,
frailty, cognitive disorders, chronic liver diseases, COPD and chronic
renal disease. These non-communicable diseases still remain a
persistent threat because of different individual risk profiles and
insufficient interventions on traditional risk factors of diseases.
Leah T Le presented neuropsychological outcomes in a
retrospective longitudinal analysis of the PISCES cohort in San
Francisco [60]. In a multivariate analysis, change in blood CD4
to CD8 cell ratio was the sole parameter independently associated
with NPZ4 score. The investigators concluded that CD4/CD8
trajectory can be used as a predictor of neurocognitive impairment
even during early infection. Sarah Beth Joseph described a
cross-sectional analysis of the THINC cohort, in which the
prevalence of asymptomatic CSF escape was found to be 6.6%
[61]. During this state of escape, there was no evidence of
neuronal damage or inflammation. Dominique Costagliola
presented data showing a 52% prevalence of cerebral small vessel
disease (CSVD) diagnosed by MRI in volunteers with well-
controlled HIV on ART [62]. Classical risk factors associated with
CSVD were age and hypertension. The only HIV-related risk factor
associated with increased risk of CSVD was a CD4 cell count nadir
<200 cells/mm3.
Vincent Marconi analysed associations between bilirubin levels and
cardiovascular events in the Veterans Aging Cohort Study [63].
After adjusting for classical cardiovascular disease (CVD) risk
factors, higher bilirubin seemed to be associated with a lower risk
of heart failure and acute myocardial infarction. Using data from
the D:A:D study, Lene Ryom analysed the risk of CVD with use
of modern ritonavir-boosted PIs, darunavir and atazanavir (ATV)
[64]. After adjustment for confounding factors, cumulative use
of darunavir, but not atazanavir, was associated with a small but
gradually increasing CVD risk. Rosan van Zoest presented an
individual-based model of CVD from the national ATHENA cohort
in order to predict CVD and evaluate interventions [65]. According
to this model, intensified monitoring and drug treatment of
hypertension and dyslipidaemia will have the greatest impact on
averting CVD events, preventing 17.0–20.0% of CVD cases
annually. The next most impactful intervention was smoking
cessation.
Leah Shepherd estimated cancer rates after smoking cessation in
39,701 HIV-infected participants in the D:A:D study [66]. Incidence
of smoking-related cancers other than lung cancer rapidly declined
following 1-year cessation. Lung cancer incidence appears to
remain elevated in HIV-infected individuals even more than 5 years
after smoking cessation.
Priscilla Hsue described IL-1beta inhibition using canakinumab (a
human monoclonal antibody) in 10 HIV-infected and virologically
suppressed individuals [67]. In this pilot study, a single dose of
canakinumab significantly reduced inflammatory markers (IL-6,
hsCRP and sCD163) and seemed to show a reduction of both
arterial inflammation and bone marrow activity in FDG-PET/CT.
Prevention of mother-to-child transmission of
HIV (PMTCT) and paediatric HIV
Issues for children with HIV and women who want to prevent their
children from being infected with HIV were at the forefront of
discussion (see CROI webcasts).There were two plenary presentations:
‘The Emerging Potential for HIV Cure for Infants, Children, andAdults’
by Jintanat Ananworanich [27], and ‘(Preventing) the Coming
Epidemic: HIV in Youth’ by Shannon Hader [68]. A highlight
symposium presented on issues for infants ‘The First Age: Infants on
the World Stage’ with four excellent talks by Roger Shapiro – ‘MTCT:
Evolving Epidemiology and Outcomes’ [69]; Martina Penazzato – ‘The
ART and Science of Infant Diagnosis’ [70]; Claire Thorne – ‘The
HIV-Exposed and Uninfected Child: What‘s to Worry?’ [71] and
Elizabeth Obimbo –‘Treatment of Newborns and Infants Living with
HIV’ [72]. A themed discussion: ‘The Impossible Dream: Population
Perspectives on 90-90-90 inAdolescents andYoungAdults’ addressed
novel models and hurdles in how to keep young people with HIV in
care [73–77].
Observational prevention of mother-to-child transmission
studies
Birth outcomes from Botswana were described where 22% of
pregnant women are HIV infected and over 90% of them receive
ART in pregnancy (Tsepamo Study) [78]. Data was extracted from
births at eight maternity wards, representing about 45% of all
births in the country. Since 2012, Botswana adopted the WHO
Option B, with all pregnant women with CD4 cell counts <350
cells/mm3 commencing life-long TDF/FTC/EFV. Of 47,124 births
that occurred from August 2014 to August 2016, 25% were
HIV-exposed and ART was started prior to conception in 5780
(48%), and 43% of women were on TDF/ FTC/EFV. Compared
to HIV-negative pregnancies, there was an increase in all adverse
birth outcomes (preterm delivery, stillbirth and small for gestational
age). Notably there were significantly fewer combined adverse birth
outcomes among women on TDF/FTC/EFV than other ART
regimens.
Do HIV-positive women on PI deliver preterm? Findings from a
UK study were presented by Graziella Favarato [79] on over 6000
women from the national study of HIV in pregnancy, 2007–2015,
which compared preterm delivery risk according to maternal ART
such as NNRTI/2NRTI, LPV/r/2NRTI and other-PI/r/2NRTI
regimens. More than 50% of women conceived on ART, and when
compared to those on an NNRTI-based regimen, one based on
LPV/r was associated with an increased risk of preterm delivery
(aOR 1.48, 95% CI 1.16–1.88); however, this was not the case
for other PI/r-based regimens (aOR 1.13 95% CI 0.89–1.43).
Kathryn Rough presented data on TDF/FTC in pregnancy showing
no increase in adverse infant birth outcomes in two large US
cohorts [80]. In the PROMISE (Promoting Maternal and Infant
Survival Everywhere) trial there was an unexpected increased risk
of very preterm birth, very low birthweight and death in infants
of women randomised to TDF/FTC/LPV/r as compared to ZDV/
3TC/LPV/r. This study compared risk of adverse infant birth
outcomes in 4646 women exposed to ZDV/3TC/LPV/r, TDF/FTC/
LPV/r and TDF/FTC/ATV/r from two large prospective US-based
cohorts. Results showed that in the US, TDF/FTC/LPV/r was not
associated with an increased risk of adverse birth outcomes
compared to ZDV/3TC/LPV/r or TDF/FTC/ATV/r. Indeed TDF/
FTC/ATV/r appeared slightly protective for preterm birth, low
birthweight and any adverse event.
A number of posters described further data from the PROMISE
trial, a comprehensive, multi-faceted, international, randomised
controlled trial of ART in pregnancy and postnatally. The antenatal
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ART and adverse birth outcomes were described by Benjamin Chi
[81]. Birth outcomes were available for 3423 HIV-infected women
across 14 sites in Africa and Asia. Women were randomised at ≥14
weeks’ gestation and not in labour into three arms: zidovudine
(ZDV) only (Arm A), ZDV/3TC/LPV/r (Arm B) or TDF/FTC/LPV/r
(Arm C). Antiretroviral regimens containing LPV/r were associated
with an elevated risk of adverse birth outcomes after adjustment
for multiple obstetrical and clinical factors. In women on LPV/r,
there were more severe outcomes on TDF/FTC compared to
ZDV/3TC. Further studies are needed to determine whether this
is an independent effect of TDF/FTC, a result of drug–drug
interactions with LPV/r, or of other factors.
The risk factors for low birthweight and preterm delivery in the
PROMISE trial were presented by Dorothy Sebikari [82]. In the
final multivariate models (adjusted for country and gestational age
at entry) analysed for 3423 women, these risk factors included
BMI, multiple gestation, prior preterm delivery, pregnancy or
chronic hypertension, intrauterine growth restriction, placental
abruption, preterm labour, oligohydramnios, premature rupture of
membranes, and antenatal ART. The investigators concluded that
public health interventions are needed to address modifiable-
obstetrical risk factors and management of pregnancy
complications, as well as optimising choice of ART regimen.
Subsequent pregnancy outcomes in women followed up in the
PROMISE Trial [83] were described by Jose H Pilotto, in a post
hoc comparison of subsequent pregnancy outcomes in
asymptomatic women (pre-ART CD4 cell count ≥400 cells/mm3)
who started ART during their first PROMISE pregnancy (2011–
2014). Women were randomised to continue (cART) or
discontinued (dART) ART after their first pregnancy, LPV/r+TDF/
FTC or ZDV/3TC were the preferred regimens. Subsequently, 17%
of women had a pregnancy with spontaneous abortions and
stillbirths, more commonly in women who had continued ART
(cART 23.6% vs dART 11.9%, P=0.02).
Alison Drake described a study of breast milk (BM) HIV viral load
(VL) among women with a recently acquired infection [84]. Among
pregnant/postpartum women with recent HIV infection, 25 women
(14 diagnosed in pregnancy, 11 postpartum), with a median time
to ART initiation of 13 days, BM VL and plasma VL were
prospectively measured. The virus was detected in BM in all
women, even those who had initiated ART during pregnancy. The
BM VL was not associated with plasma VL or months since ART
initiation. The authors importantly concluded that further analysis
of BM viral dynamics in women on ART is warranted.
Prevention of mother-to-child transmission and the neonate
Extending the narrow range of ART available to the HIV-exposed
neonates is very important. The pharmacokinetic (PK) studies
presented demonstrated dosing and safety for raltegravir as
presented by Diana Clarke [85], and for nevirapine for low
birthweight infants by Adrie Bekker [86]. A triple ART regimen
(NVP/ZDV/3TC) for high-risk infants was also shown to be safe
[87]. Monoclonal antibodies against HIV treatment has exciting
potential for prevention and treatment with reassuring safety and
PK data for VRC01 in HIV-exposed neonates as presented by
Coleen Cunningham [88].
Data presented at the Conference highlighted that a cost is
attached to PMTCT. Although all ART regimens are highly effective
in preventing MTCT through viral suppression, adverse outcomes
of pregnancy, including stillbirth, premature delivery and small-
for-gestation age infants are more common, and more so with
certain regimens. These results are of particular importance for
resource-poor settings. Adverse outcomes were demonstrated in
randomised controlled trials and observational cohorts. As Roger
Shapiro concluded in his talk, there is a trade-off between using
ART to maximise PMTCT and adverse birth outcomes: ‘For the
past two decades, the public health focus has been to expand
ART availability in pregnancy and from a public health standpoint
it has been difficult to address the growing evidence for adverse
birth outcomes. We now need to move into a new era where we
remain committed to using ART in pregnancy, but also work to
understand and address its complications.’
Paediatric studies
Optimising early infant diagnosis (EID) of HIV
Owing to the need to detect the virus, delay in diagnosis and
treatment for HIV-infected infants is an international issue. Ilesh
Jani demonstrated the effective use of a point-of-care test on ART
initiation rates in infected infants in Mozambique [89]. Nurses in
eight intervention primary health clinics (PHC) implemented the
Alere q HIV-1/2 Detect POC EID test at 4–6 weeks of age (POC
arm) and eight control PHCs collected dried blood spots for EID
testing at standard of care (SOC arm) reference laboratories. Access
to POC significantly increased ART initiation and retention in care.
Decentralisation of EID could accelerate ART initiation in
challenging environments, thereby improving global paediatric ART
treatment rates.
Treatment with ART that is initiated soon after primary infection
influences the seeding of the viral reservoir with beneficial effects
for virological control. Infants are an important group in whom
HIV infection can be identified soon after infection. In this study
of very early diagnosed and ART-treated infants, from the Rahima
Moosa Mother and Child Hospital, Johannesburg, virological
dynamics were described [90]. Of 68 infants, 50% started
treatment within 2 days and 90% by day 15. Six months later,
11% had persistently high HIV RNA, 35% had a declining trajectory
and 54% had declined to undetectable levels. Of those with full
suppression by 6 months, 30% changed to a negative diagnostic
HIV-1 DNA PCR during follow-up. The authors concluded that
many clinical and social challenges may affect the variability in
virological response in this high-risk group of infants.
Moherndran Archary addressed the issue of HIV-positive children
with severe acute malnutrition (SAM) and initiation of ART in this
clinically important randomised trial of 82 children [91]. Results
showed no difference in mortality on early (<14 days) versus
delayed ART (>14 days or until recovery). Although the response
at 48 weeks was not different between the two groups in terms
of CD4, VL and anthropometric parameters, the rates of CD4
increase, VL decrease, and WAZ and HAZ scores recovery favoured
the delayed ART arm. The authors concluded that ART initiation
in children with SAM should be delayed for at least 2 weeks after
starting nutritional rehabilitation. This helps to simplify the early,
complex management of these very sick children.
Long-term adherence to ART is demanding, particularly for young
people. AnnaTurkova presented extended data from the BREATHER
study according to the original randomisation continuous therapy
(CT) versus 5/7 days short cycle therapy (SCT) [92]. Non-inferiority
of viral load suppression between the two arms was demonstrated
over a median 3.6 years follow-up, thus demonstrating that EFV/2
NRTI first line may be used effectively and safely if taken 5 days
a week, a forgiving option for young people.
A global analysis of the predictors of switch to second-line ART
in HIV-positive children was presented by Kara Wools-Kalousitan
[93]. The CIPHER cohort collaboration brings together data on
more than 93,000 children with HIV, worldwide. In this analysis
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of 12 cohort networks within this study, predictors of switch to
second-line ART were assessed in 3883 children. The median age
at ART switch was 8.6 years, the median first ART duration was
35 months with 85% of children switching from NNRTI to PI. The
factors associated with a switch were male sex, older age, earlier
calendar years, NNRTI, viral load monitoring and region. There
was a marked difference by regions, with a faster time to switch
with targeted and routine VL monitoring. There was delayed switch
and under-recognised treatment failure with clinical or CD4 cell
monitoring. These data are important when considering the
scale-up of HIV-1 viral load testing in low- and middle-income
countries, which will increase the more rapid detection of treatment
failure and the need for second-line ART for children.
Looking at HIV detection and latent reservoirs in children, Shalena
Naidoo described 10 children (post-CHER participants) who had
initiated ART within 1 year of birth and remained undetectable
until the age of 7–8 years. Median cell-associated DNA was 38
copies/million (M) cells (range 4.5–186). Inducible HIV-1 RNA
could be detected in four children, with all virus outgrowth assay
supernatants collected remaining negative for p24 antigen [94].
The impact of the HIV reservoir size was studied by Mark Pankau
in 14 Kenyan infants whowere randomised to treatment interruption
after 24 months of ART (median age of 28.9 months) after early
treatment initiation (median age of 4.8 months) inThe Optimizing
Pediatric HIVTreatment study. Those children who continued ART
had a median of 168 copies of HIV-1 DNA/M PBMCs 24 months
after ART initiation and of 50 copies 18 months later. Infants
randomised to interruption had a median of 90 copies at 24 months
and of 184 copies after 18 months of ART interruption showing
a continuous decay in the viral reservoir while on ART and not a
very substantial increase with ART interruption [95]. Leila Giron
described an increased latent reservoir size in children with subtype
D (mean duration of ART of 566 days) as compared to those with
subtype A (PROMOTE paediatrics trial) [96].
Finally, Emily Adland described the restoration of anti-HIV-1 CD4
T cell activity in children treated with ART, even for those of only
12 months of age, with strong IL-2 gag specific CD4 T cell
responses. The treatment duration was associated with CD4 and
CD8 T cell polyfunctionality and decreased expression of immune
activation and inhibitory receptors [97].
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